BIO Investor Forum Presenter Profiles

SAN FRANCISCO--(BUSINESS WIRE)--BIO Investor Forum takes place October 29, 2008 - October 31, 2008 at the Palace Hotel in San Francisco. Listed below are the BIO Investor Forum presenter profiles. For in-depth information about the event, visit http://investorforum.bio.org/opencms/bif/2008/.

Business Wire is the official news wire for BIO Investor Forum. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Company:	Acceleron Pharma
Date of Presentation:	October 29, 2008
Media Contact:	Paul Kidwell, 617-296-3854
Phone:	617-649-9234
E-mail:	[e-mail]
Web:	www.acceleronpharma.com
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. ACE-011, a novel bone forming agent, is the Company’s lead program and is being developed to reverse bone loss in diseases such as cancer-related bone loss. ACE-031, the lead program in our muscle franchise is being developed to treat serious diseases involving the loss of muscle mass and function. In addition, the company is advancing through preclinical development product candidates that control angiogenesis and others that inhibit fat accumulation.
Company:	Allon Therapeutics Inc.
Date of Presentation:	Thursday, October 30, 1:45 pm
Ticker Symbol & Exchange:	TSX:NPC
Media Contact:	Aaron Keay, Director, Investor Relations
Phone:	C: [phone]
E-mail:	[e-mail]
Web:	www.allontherapeutics.com
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon’s lead clinical program is focused on Alzheimer’s disease. In February 2008 the Company announced positive results in a Phase IIa clinical study for amnestic MCI, a precursor to Alzheimer’s disease, showing statistically significant, dose dependant, and durable efficacy on human memory. The Company also has a Phase II trial underway in schizophrenia cognitive impairment.
The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company) and based in Vancouver.
Company:	Athersys, Inc.
Date of Presentation:	October 30th, 2008
Ticker Symbol & Exchange:	NASDAQ: ATHX
Media Contact:	William (B.J.) Lehmann
Phone:	[phone]
E-mail:	[e-mail]
Web:	www.athersys.com
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company has multiple clinical and preclinical stage programs. In addition to its lead product candidate, ATHX-105 for the treatment of obesity, the Company is developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders. Athersys is also developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.
Company:	BioMimetic Therapeutics, Inc
Date of Presentation:	October 30 at 2:45
Ticker Symbol & Exchange:	Nasdaq BMTI
Media Contact:	Kearstin Patterson
Phone:	615-517-6112
E-mail:	[e-mail]
Web:	www.biomimetics.com
BioMimetic Therapeutics is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in 2005 for its first product, GEM 21S, for regeneration of bone and periodontal tissue loss resulting from periodontal disease. Currently, the Company has clinical trials ongoing with its product candidates Augment™ Bone Graft and Augment™ Injectable Bone Graft in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's lead product candidates all combine recombinant human platelet derived growth factor (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
Company:	Celladon Corporation
Date of Presentation:	Friday, October 31, 2008, 9:00 a.m.
Media Contact:	Stacie D. Byars, WeissComm Partners
Phone:	206.660.2588
E-mail:	[e-mail]
Web:	www.celladon.net
Celladon is a privately held biotechnology company developing molecular therapies for the treatment of heart failure. The company’s products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladon’s first generation product candidate, MYDICAR®, delivers the gene for the SERCA2a enzyme and is being tested in Phase 1 and 2 clinical trials. Celladon is also developing small molecule activators of SERCA2a for acute heart failure. The Company is based in La Jolla, California and founded by Roger J. Hajjar, M.D and Kenneth R. Chien M.D., Ph.D. Current investors include Enterprise Partners, Venrock Associates, and Johnson & Johnson Development Corporation. To learn more about Celladon, visit Celladon’s website at www.celladon.net.
Company:	Epilepsy Therapy Project
Date of Presentation:	10/30/2008
Media Contact:	Joyce Cramer
Phone:	540-687-8077
E-mail:	[e-mail]
Web:	http://www.epilepsy.com/etp/about_etp
The Epilepsy Therapy Project is a 501 (c) (3) nonprofit organization dedicated to a singular focus: overcoming the funding gaps and roadblocks that slow the progress of new therapies from the lab to the patient. Epilepsy Therapy Project seeks to improve incentives and encourage commercial investment in new therapies. Acting as both a catalyst and clearing house for innovative research and the early commercialization of new therapies, the Epilepsy Therapy Project brings together financial resources, scientific insights and business expertise from leading academic and commercial industry participants. To invest your contributions effectively, we have assembled an outstanding staff and team of clinicians, researchers, and pharmaceutical, biotechnology, and finance industry advisors. These scientific and business advisory board members make funding decisions and provide support to advance.
Company:	ImmunoVaccine Technologies Inc.
Date of Presentation:	October 30, 2008; 2:15pm
Media Contact:	Jennifer Ayotte
Phone:	[phone] ex 315
E-mail:	[e-mail]
Web:	www.immunovaccine.com
ImmunoVaccine Technologies Inc. (IVT) is a private clinical-stage biotechnology company developing infectious disease and therapeutic cancer vaccines for human health. IVT’s vaccines which use breakthrough VacciMax® and DepoVax™ enhancement and delivery platforms with validated antigens will position IVT as a key player in development of premium vaccine products. In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal Health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.
Company:	InNexus Biotechnology Inc.
Date of Presentation:	October 30, 2009
Ticker Symbol & Exchange:	TSX: IXS.V OTCBB: IXSBF.OB
Media Contact:	Jeff Morhet
Phone:	480-862-7500
E-mail:	[e-mail]
Web:	www.ixsbio.com
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications.
In a short period of time, InNexus has assembled facilities, resources, a stellar Scientific Advisory Board, staff and milestones yielding multiple pre-clinical candidates targeting cancer and other commercial opportunities. InNexus has launched into pre-clinical development its first four products, DXL625 and DXLr120, both for the prospective treatment of non-Hodgkin’s lymphoma and other immune disorders that include rheumatoid arthritis, DXL702 for the treatment of breast cancer and DXL1215 targeting endometriosis.
Company:	ISTA Pharmaceuticals, Inc.
Date of Presentation:	Friday, October 31, 2008
Ticker Symbol & Exchange:	ISTA - Nasdaq
Media Contact:	Justin Jackson
Phone:	212-213-0006
E-mail:	[e-mail]
Web:	www.istavision.com
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S.
Company:	MethylGene Inc.
Date of Presentation:	October 30, 2008 at 9:00 a.m. PT
Ticker Symbol & Exchange:	MYG : TSX
Media Contact:	Karen McTavish
Phone:	514-337-3333
E-mail:	[e-mail]
Web:	www.methylgene.com
MethylGene Inc. is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company’s product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases which is in Phase I clinical trials for solid tumor cancers; MGCD290, a fungal Hos2 (HDAC) inhibitor used in combination with azoles for fungal infections which is also in a Phase I clinical trial; and MGCD0103, an oral, isoform-selective HDAC inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies and is licensed to Celgene Corporation and Taiho Pharmaceutical.
Company:	Oncolytics Biotech Inc.
Date of Presentation:	Oct. 29, 2008
Ticker Symbol & Exchange:	TSX:ONC, NASDAQ:ONCY
Media Contact:	Cathy Ward
Phone:	403.670.7370
E-mail:	[e-mail]
Web:	www.oncolyticsbiotech.com
Oncolytics Biotech Inc. is conducting a broad clinical trial program in the U.S. and the U.K. with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes 12 Phase I/II or Phase II human trials examining REOLYSIN® alone or in combination with radiation, chemotherapy, or immune modulation.
This broad clinical program is designed to identify targets for late-stage registration trials with REOLYSIN®. The current program is treating patients with a wide variety of advanced cancers including head & neck, sarcoma, non-small cell lung, melanoma and ovarian.
Company:	Zelos Therapeutics, Inc.
Date of Presentation:	October 30, 2008
Media Contact:	Alan Roemer, CFO
Phone:	[phone]
E-mail:	[e-mail]
Web:	http://www.zelostherapeutics.com
Zelos Therapeutics is developing therapeutics for the treatment of osteoporosis and other bone diseases. Our lead clinical compound, ZT-031, is a parathyroid hormone (PTH) analog that has demonstrated increases in bone formation. ZT-031 is entering Phase 3 registration studies and has the potential to become a leading therapy to treat osteoporosis in the growing PTH market. In addition, Zelos Therapeutics is evaluating potential orthopedic uses of ZT-031’s bone formation properties for fracture repair, trauma and use as a surgical adjunct.

Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS, and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services.

Note to Event Organizers: Add your trade show, conference, or event to http://www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow [at] businesswire.com.